bioMerieux SA 2025 IR
The report outlines bioMérieux's financial and sustainability performance for the fiscal year 2025. The company achieved consolidated sales of €4,070 million, representing 6.2% organic growth, driven by its molecular biology and industrial applications. On the sustainability front, bioMérieux received SBTi approval for its net-zero target by 2050, committing to reduce absolute Scopes 1 and 2 emissions by 62% by 2034. Additionally, the company achieved its 2025 diversity target with women representing 44.4% of the Executive Committee and maintained its Gold EcoVadis rating.
Company: bioMerieux SA
Sector: Health Care
Country: France
Year: 2025
Type: IR
Pages: 400
bioMerieux SA
Universal Registration Document
The report outlines bioMérieux's financial and sustainability performance for the fiscal year 2025. The company achieved consolidated sales of €4,070 million, representing 6.2% organic growth, driven by its molecular biology and industrial applications. On the sustainability front, bioMérieux received SBTi approval for its net-zero target by 2050, committing to reduce absolute Scopes 1 and 2 emissions by 62% by 2034. Additionally, the company achieved its 2025 diversity target with women representing 44.4% of the Executive Committee and maintained its Gold EcoVadis rating.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees